Dezrinitis nasal spray dosed 50mkg / dose, 140 doses

- Hypersensitivity to mometasone or any of the components of the drug;

- children's age (with seasonal and year-round allergic rhinitis - up to 2 years; with acute sinusitis or exacerbations of chronic sinusitis - up to 12 years; with nasal polyposis - up to 18 years);

- recent surgery or nose injury - before the wound heals (due to the inhibitory effect of GCS on the healing process).

Carefully :

The drug Dezrinit should be used with caution in case of tuberculous infection (active or latent) of the respiratory tract, untreated fungal, bacterial, systemic viral infection or infection caused by Herpes simplex with eye damage (as an exception, it is possible to prescribe the drug for the listed infections as directed by a doctor), the presence of untreated local infection involving the nasal mucosa in the process.

Intranasally. Inhalation of the suspension contained in the vial is carried out using a special dispensing nozzle on the vial.

Before using the Dezrinit nasal spray for the first time, it must be 'calibrated'.

Do not pierce the nasal applicator.

To 'calibrate', press the dispensing nozzle 10 times until splashes appear, indicating that the product is ready for use.

Tilt your head and inject the medicine into each nostril as directed by your healthcare provider.

If the drug has not been used for 14 days or more, press the dispensing nozzle 2 times until splashes appear.

Tilt your head and inject the medicine into each nostril as directed by your healthcare provider.

Cleaning the dispensing tip

It is important to clean the dispensing tip regularly to avoid malfunctioning. Remove the dust cap, then carefully remove the spray tip. Thoroughly rinse spray tip and dust cap in warm water and rinse under tap.

Do not try to open the nasal applicator with a needle or other sharp object, as this will damage the applicator and may result in the inappropriate dose of the drug.

Dry the cap and knee pad in a warm place. Then attach the spray tip to the bottle and screw the dust cap back onto the bottle. When using the nasal spray for the first time after cleaning, recalibrate by pressing the dispensing tip 2 times.

Shake the bottle vigorously before each use.

Treatment of seasonal and perennial allergic rhinitis

Adults (including the elderly) and adolescents from the age of 12

The recommended prophylactic and therapeutic dose of the drug is 2 inhalations (50 mcg each) in each nostril once a day (total daily dose - 200 mcg). Upon reaching the therapeutic effect for maintenance therapy, it is possible to reduce the dose by 1 inhalation in each nostril once a day (total daily dose - 100 mcg).

If a decrease in the symptoms of the disease cannot be achieved by using the drug in the recommended therapeutic dose, the daily dose can be increased to 4 inhalations in each nostril once a day (total daily dose - 400 mcg).

After reducing the symptoms of the disease, a dose reduction is recommended

The onset of action of the drug is usually noted clinically as early as 12 hours after the first use of the drug.

Children 2-11 years old :

The recommended therapeutic dose is 1 inhalation (50 mcg) in each nostril once a day (total daily dose is 100 mcg).

The use of the drug in young children requires adult assistance.

Adjunctive treatment of acute sinusitis or exacerbation of chronic sinusitis

Adults (including the elderly) and adolescents from the age of 12

The recommended therapeutic dose is 2 inhalations (50 mcg each) in each nostril 2 times a day (total daily dose - 400 mcg).

If a decrease in the symptoms of the disease cannot be achieved by using the drug in the recommended therapeutic dose, the daily dose of the drug can be increased to 4 inhalations in each nostril 2 times a day (total daily dose - 800 mcg). After reducing the symptoms of the disease, a dose reduction is recommended

Treating acute rhinosinusitis without evidence of severe bacterial infection

The recommended dose for adults and adolescents is 2 inhalations of 50 mcg in each nasal passage 2 times a day (total daily dose of 400 mcg). If symptoms worsen during treatment, consult a specialist.

Treatment of nasal polyposis

Adults (including the elderly) from 18 years old

The recommended therapeutic dose is 2 injections (50 mcg each) into each nostril 2 times a day (total daily dose - 400 mcg).

After reducing the symptoms of the disease, it is recommended to reduce the dose to 2 inhalations (50 mcg each) in each nostril once a day (total daily dose - 200 mcg).

1 dose contains:

active substance: mometasone furoate monohydrate (in terms of mometasone furoate) - 0.052 mg (0.050 mg);

excipients: avicel RC-591 [microcrystalline cellulose, sodium carmellose] 2.00 mg; glycerol 2.10 mg; benzalkonium chloride solution 500 g / l 0.04 mg; polysorbate-80 0.01 mg; citric acid monohydrate 0.20 mg; sodium citrate dihydrate 0.28 mg; water for injection a sufficient amount up to 100.00 mg.

- Hypersensitivity to mometasone or any of the components of the drug;

- children's age (with seasonal and year-round allergic rhinitis - up to 2 years; with acute sinusitis or exacerbations of chronic sinusitis - up to 12 years; with nasal polyposis - up to 18 years);

- recent surgery or nose injury - before the wound heals (due to the inhibitory effect of GCS on the healing process).

Carefully :

The drug Dezrinit should be used with caution in case of tuberculous infection (active or latent) of the respiratory tract, untreated fungal, bacterial, systemic viral infection or infection caused by Herpes simplex with eye damage (as an exception, it is possible to prescribe the drug for the listed infections as directed by a doctor), the presence of untreated local infection involving the nasal mucosa in the process.

Active substance :

Mometasone

Dosage form:

metered dose nasal spray

Composition :

1 dose contains:

active substance: mometasone furoate monohydrate (in terms of mometasone furoate) - 0.052 mg (0.050 mg);

excipients: avicel RC-591 [microcrystalline cellulose, sodium carmellose] 2.00 mg; glycerol 2.10 mg; benzalkonium chloride solution 500 g / l 0.04 mg; polysorbate-80 0.01 mg; citric acid monohydrate 0.20 mg; sodium citrate dihydrate 0.28 mg; water for injection a sufficient amount up to 100.00 mg.

Description:

Milky-white suspension without agglomerates, placed in a white polyethylene bottle equipped with a dosing device and a transparent polypropylene cap.

Pharmacotherapeutic group:

Topical glucocorticosteroid

ATX:
R.01.AD09

Pharmacodynamics:

Mometasone is a synthetic glucocorticosteroid (GCS) for topical use. It has anti-inflammatory and anti-allergic effects. The local anti-inflammatory effect of the drug is manifested when it is used in doses at which there are no systemic effects.

Inhibits the release of inflammatory mediators. Increases the production of lipomodulin, which is an inhibitor of phospholipase A, which causes a decrease in the release of arachidonic acid and, accordingly, inhibition of the synthesis of metabolic products of arachidonic acid - cyclic endoperoxides, prostaglandins. Prevents marginal accumulation of neutrophils, which reduces inflammatory exudate and the production of lymphokines, inhibits the migration of macrophages, and leads to a decrease in the processes of infiltration and granulation. Reduces inflammation by reducing the formation of chemotaxis substance (effect on late allergy reactions), inhibits the development of an immediate allergic reaction (by inhibiting the formation of arachidonic acid metabolites and reducing the release of inflammatory mediators from mast cells).

In studies with provocative tests with the application of antigens to the nasal mucosa, a high anti-inflammatory activity of the drug was demonstrated both in the early and late stages of an allergic reaction.

When compared with placebo, a decrease in the level of histamine and eosinophil activity was found, as well as a decrease (compared to the initial) in the number of eosinophils, neutrophils and proteins of epithelial cells.

Pharmacokinetics:

With intranasal administration, the systemic bioavailability of mometasone fuorate is <1% (with a sensitivity of the method for the determination of 0.25 pg / ml). A small amount of the active substance, which can enter the gastrointestinal tract (GIT) during intranasal administration, is absorbed to a small extent and is actively biotransformed during the 'first pass' through the liver.

Indications for use

- Seasonal and year-round allergic rhinitis in adults, adolescents and children from 2 years of age;

- acute sinusitis or exacerbation of chronic sinusitis in adults (including the elderly) and adolescents from 12 years old - as an auxiliary therapeutic agent in antibiotic treatment;

- acute rhinosinusitis with mild to moderate symptoms without signs of severe bacterial infection in patients aged 12 years or more,

- preventive treatment of moderate and severe seasonal allergic rhinitis in adults and adolescents from 12 years of age (recommended two to four weeks before the expected start of the dusting season);

- nasal polyposis, accompanied by impaired nasal breathing and smell, in adults (over 18 years old).

Contraindications

- Hypersensitivity to mometasone or any of the components of the drug;

- children's age (with seasonal and year-round allergic rhinitis - up to 2 years; with acute sinusitis or exacerbations of chronic sinusitis - up to 12 years; with nasal polyposis - up to 18 years);

- recent surgery or nose injury - before the wound heals (due to the inhibitory effect of GCS on the healing process).

Carefully :

The drug Dezrinit should be used with caution in case of tuberculous infection (active or latent) of the respiratory tract, untreated fungal, bacterial, systemic viral infection or infection caused by Herpes simplex with eye damage (as an exception, it is possible to prescribe the drug for the listed infections as directed by a doctor), the presence of untreated local infection involving the nasal mucosa in the process.

Pregnancy and lactation:

Special studies on the safety of the use of mometasone during pregnancy and during breastfeeding have not been conducted.

As with the use of other nasal corticosteroids, the drug Dezrinit should be prescribed during pregnancy and during breastfeeding only if the expected benefit from its use outweighs the potential risk to the fetus and newborn.

Newborns whose mothers used GCS during pregnancy should be carefully examined to identify possible adrenal hypofunction.

Method of administration and dosage